Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation

Monomorphic post-transplant lymphoproliferative disorder (M-PTLD) occurring after solid organ transplant histologically resembles aggressive non-Hodgkin lymphomas, with diffuse large B-cell lymphoma being the most common. In a cohort of 40 patients with DLBCL-type M-PTLD, inferior progression free s...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2021-01, Vol.62 (1), p.86-94
Main Authors: Voorhees, Timothy J., Kannan, Kavya K., Galeotti, Jonathan, Grover, Natalie, Vaidya, Rakhee, Moore, Dominic T., Montgomery, Nathan D., Beaven, Anne W., Dittus, Christopher
Format: Article
Language:English
Subjects:
Disease Progression
Epstein-Barr Virus Infections
Humans
Lymphoma, Large B-Cell, Diffuse - diagnosis
Lymphoma, Large B-Cell, Diffuse - etiology
Lymphoproliferative Disorders - diagnosis
Lymphoproliferative Disorders - etiology
monomorphic
Organ Transplantation - adverse effects
outcome
Post-transplant lymphoproliferative disorder
Progression-Free Survival
PTLD
survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monomorphic post-transplant lymphoproliferative disorder (M-PTLD) occurring after solid organ transplant histologically resembles aggressive non-Hodgkin lymphomas, with diffuse large B-cell lymphoma being the most common. In a cohort of 40 patients with DLBCL-type M-PTLD, inferior progression free survival (PFS) was observed for Revised International Prognostic Index (R-IPI) >2 (p = 0.01) and high-risk pathologic features (p = 0.02), defined by double expressor lymphoma, MYC rearrangement, or increased copy number of either MYC or BCL2. Overall survival (OS) was inferior in R-IPI >2 (p = 0.002) and high-risk pathologic features (p = 0.003). Combining both R-IPI >2 and high-risk pathologic features resulted in well-delineated good, intermediate, and poor risk groups of DLBCL-type M-PTLD with respect to both PFS and OS (p 
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2020.1821006